Odyssey Therapeutics, Inc.

Triana Biomedicines has reeled in a $120 million Series B — $10 million higher than its 2022 Series A — to collect proof-of-concept data for its lead experimental medicine and develop further treatment candidates in the molecular glue space. The Wednesday morning financing comes a year after the Lexington, MA-based startup struck a $49 million upfront partnership with Pfizer . That deal, across multiple therapeutic areas such as oncology, could balloon to more than $1.5 billion in payouts for Triana. It marks at least the 22nd megaround financing since Sept. 30, according to an Endpoints News tally, as the biotech industry has picked up momentum headed into the new year. Ascenta Capital and Bessemer Venture Partners co-led the Series B. Ascenta has been in the works for years and unveiled its $325 million first fund in October. The Florida-based VC firm, from former Moderna leaders Lorence Kim and Evan Rachlin, has backed other drug developers like ADARx, Odyssey Therapeutics and Alpha-9 Oncology. Kim is joining the Triana board alongside Bessemer’s Andrew Hedin. Other investors joined Triana’s capitalization table for the first time, including YK Bioventures, Regeneron Ventures, Invus and Finchley Healthcare Ventures. Existing backers like RA Capital and Atlas Venture returned. RA and Atlas teamed up to form Triana a few years ago. RA had built a machine learning algorithm to find optimal pairings for E3 ligases and target proteins. Meanwhile, Atlas created a way to mine loads of possible molecular glue structures. At the time of the Pfizer partnership, CEO Patrick Trojer told Endpoints News that Triana could get into the clinic as soon as 2026. A spokesperson told Endpoints on Wednesday that Triana expects to enter the clinic by the end of this year. On Thursday, Triana unveiled its lead candidate, called TRI-611. The experimental medicine will be aimed at ALK+ non-small cell lung cancer. Triana said it anticipates selecting a second product candidate next year. Editor’s note: This story was updated to include a detail on clinical trial timelines from a Triana spokesperson.

Two years after Terray Therapeutics inked a multi-target deal with Bristol Myers Squibb to develop small molecules using its AI technology, the biotech said Wednesday it has achieved a discovery milestone.While Terray can't share too many details about the programme, CEO Jacob Berlin told FirstWord the milestone adds to the company's confidence that its AI platform, dubbed Experimentation Meets Machine Intelligence (EMMI), can deliver across a broad set of target classes and indications. "This milestone highlights one of the key advantages of EMMI — the ability to discover and optimise molecules against difficult and novel targets where there is often little to no previous chemistry knowledge," Berlin said.Reaching the right molecule, fasterThe news follows Terray's unveiling of EMMI in November. The platform combines ultra-miniaturised hardware for molecule testing together with a highly-automated lab and a full-stack AI.Its chemistry foundation model, COATI, now in its third generation, is like "GPT for molecules," according to Terray. By encoding molecules in mathematical latent space, they can be manipulated and investigated by AI models, and "translated" back into molecules when needed. Terray, which raised $120 million in funding last year from investors including NVIDIA and Madrona Ventures, has collected over 13 billion target-molecule measurements into what it calls "the world’s largest precise chemistry dataset" — and it continues to grow at 1 billion measurements per quarter (see – Spotlight On: 'A year of balance' — Realistic expectations for AI in 2025). "EMMI shines by mining this database to find starting points for difficult targets where other approaches have struggled or failed," he noted. The most promising molecules are then optimised with Terray's generative, predictive and selection AI models and evaluated with its experimental workflows for at-scale testing. With EMMI to aid in molecule selection, Terray's benchmarking tests suggest its platform arrived at the best molecule three times faster than other AI technologies, with a similar cost reduction rate. "It is very common to have AI predictions on thousands to millions of molecules, but it is only possible to make and test tens of these in a given week. Picking the right set of molecules has for too long relied on human intuition or basic models that are biased towards the most highly ranked molecules but do not consider how uncertain the ranking is," Berlin explained. "Terray is a pioneer in developing a model that can quantify the uncertainty in the predictions of other models and then optimally select the right set of molecules to test." Series of partnershipsIn addition to its tie-up with BMS, Terray has a discovery deal with Gilead Sciences, similarly focused on "undruggable" targets. The biotech is also working with Google-founded Calico on age-related diseases, and has a collaboration with Odyssey Therapeutics to co-develop compounds against transcription factors for immunology and inflammatory diseases.Internally, Terray is developing an immunology pipeline, though its drug development work is remaining under wraps until "the science is ready," Berlin said. He noted that "EMMI is used across Terray's entire pipeline and has identified and optimised novel chemical scaffolds time and time again."

Artios Pharma 完成1.15亿美元融资，加速推进肿瘤治疗管线 Artios Pharma 正在推进多项肿瘤创新药研发，其中最核心的项目是 alnodesertib，目前分别用于 二线胰腺癌 和 三线结直肠癌 的临床试验。 公司在周一宣布已完成 1.15 亿美元 D 轮融资，资金主要支持其肿瘤管线的进一步开发。 重点投入将用于 alnodesertib 的推进。根据 4 月公布的数据，alnodesertib 联合低剂量伊立替康 在 ATM 蛋白阴性 的晚期或转移性实体瘤患者中，取得了 50% 的确证客观缓解率（ORR）。而在“ATM低表达”患者亚组中，响应率为 22%。 凭借本次融资，Artios 计划在上述两类癌症队列中进一步扩大 ATM阴性患者 的入组规模。 此外，D 轮融资还将支持 Artios 推进 ART6043 的 II 期临床试验。该药是一款 DNA 聚合酶 Theta（POLQ）抑制剂，计划用于 BRCA 突变、HER2 阴性的乳腺癌患者。 ART6043 的最新临床数据与投资背景：耐受性良好，可望与Lynparza联用 在 2025 年 9 月举行的 欧洲肿瘤内科学会年会（ESMO） 上公布的最新数据表明，ART6043 具备 每日一次给药（once-daily） 的可行性，同时也显示其有望与阿斯利康和默沙东联合开发的 PARP 抑制剂 Lynparza（奥拉帕尼） 联合使用。 Artios 当时指出，ART6043 的安全性表现“温和（benign）”，整体耐受性良好。 本轮融资由公司最早的投资方 SV Health Investors 领投，新投资方 RA Capital Management 加入，Janus Henderson Investors 也参与了此次投资，并与 Artios 现有的投资者队列共同支持公司发展。 2025 年是生物医药领域“大额融资”频出的年份。其中包括： Isomorphic Labs 在 3 月获得 6 亿美元融资； Odyssey Therapeutics 在 9 月完成 2.13 亿美元 D 轮融资； Kriya Therapeutics 在 8 月筹得 3.133 亿美元； 专注肥胖症治疗的 Verdiva Bio 于 1 月以 4.1 亿美元 完成亮相，成为今年迄今规模最大的 A 轮融资。 此外，两个专注脱发治疗的生物技术公司在上月也取得大额融资： Pelage Pharmaceuticals 获得 1.2 亿美元 B 轮融资； Veradermics 完成 1.5 亿美元 C 轮融资。 ------------------------------ 从这次 Artios Pharma 的融资与临床数据可以看出两个明显趋势：一是 DNA 修复靶点（如POLQ、ATM缺失）正成为抗肿瘤研发的新热门；二是资本依旧高度青睐具备明确生物标志物定位、可与现有疗法形成协同的精准药物。 ART6043 的 once-daily 给药方式、良好耐受性，以及与奥拉帕尼潜在的组合可能，使其在 PARP 抑制剂疗效瓶颈后，成为值得关注的“下一代 DNA 修复疗法”。而在 D 轮融资普遍收紧的背景下，Artios 能拿到 1.15 亿美元，也说明产业界仍在追捧能“找到正确人群、讲清楚机制”的公司。 整体而言，这不是一篇大新闻，却是一个小而稳的信号：精准肿瘤学的下一轮竞争，将围绕“靶点深度”与“组合策略”展开，而不是盲目扩管线的故事。 🔹本文供医学科普使用，不构成医疗建议。本文内容基于公开资料整理，包括但不限于Fierce Biotech、The Guardian、Reuters、Nature、STAT News 等权威媒体与期刊。所有翻译与解读仅用于知识分享与医学科普，不构成任何医疗建议或临床指导。 🔹本文由「思索新知」团队基于海外权威资料整理，致力于提供可信赖的全球医疗科技动态。